Navigation Links
Third Wave posts $22 million loss, stock rises

Madison, Wis. A decline in research revenue led Third Wave Technologies to a loss of $22.3 million in 2005, or 54 cents a share, but because the loss was expected share price rose slightly in light trading.

As a company in transition, Third Wave expected something of a rough patch. It has a new focus on the clinical market, rather than research a......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 03/01/06


Page: 1

Related biology technology :

1. Third Wave files countersuit vs. Digene in patent case
2. Third Wave reports net loss of $18.9M for 2006
3. Stratagene to pay Third Wave $10.75M in patent case
4. Third Wave responds to Digene patent lawsuit
5. Third Wave seeks approval of Cystic Fibrosis test
6. Third Wave Technologies to raise $14.9M through private debt
7. Third Wave reports $5.2M third quarter loss
8. Third Wave reports another loss, stronger sales
9. Napier joins board of Third Wave Technologies
10. Third Waves revenues rebound
11. Third Wave reports clinical growth, continued loss
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Third Wave posts million loss stock rises

Breaking Biology News(10 mins):Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Pathological gambling may be successfully treated with medications for substance addiction 2HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid Beta Accumulation a Hallmark of Alzheimers Disease 56123 1HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid Beta Accumulation a Hallmark of Alzheimers Disease 56123 2HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid Beta Accumulation a Hallmark of Alzheimers Disease 56123 3Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive 28R 29 13823 1Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive 28R 29 13823 2Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive 28R 29 13823 3Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive 28R 29 13823 4Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive 28R 29 13823 5Service Dogs Help Traumatized Veterans Heal 56119 1Service Dogs Help Traumatized Veterans Heal 56119 2Service Dogs Help Traumatized Veterans Heal 56119 3